title: Neuroprotective Effects of Isosteviol Sodium Injection on Acute Focal Cerebral Ischemia in Rats.
abstract: Previous report has indicated that isosteviol has neuroprotective effects. However, isosteviol was administered preventively before ischemia and the inclusion criteria were limited. In the present study, a more soluble and injectable form of isosteviol sodium (STVNA) was administered intravenously hours after transient or permanent middle cerebral artery occlusion (tMCAO or pMCAO) to investigate its neuroprotective effects in rats. The rats were assessed for neurobehavioral deficits 24 hours after ischemia and sacrificed for infarct volume quantification and histology evaluation. STVNA 10 mg·kg(-1) can significantly reduce the infarct volumes compared with vehicle in animals subjected to tMCAO and is twice as potent as previously reported. Additionally, the therapeutic window study showed that STVNA could reduce the infarct volume compared with the vehicle group when administered 4 hours after reperfusion. A similar effect was also observed in animals treated 4 hours after pMCAO. Assessment of neurobehavioral deficits after 24 hours showed that STVNA treatment significantly reduced neurobehavioral impairments. The number of restored NeuN-labeled neurons was increased and the number of TUNEL positive cells was reduced in animals that received STVNA treatment compared with vehicle group. All of these findings suggest that STVNA might provide therapeutic benefits against cerebral ischemia-induced injury.
authors.affiliation: Pre-Incubator for Innovative Drug & Medicine, South China University of Technology, Guangzhou 510006, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Hu
authors.affiliation: Pre-Incubator for Innovative Drug & Medicine, South China University of Technology, Guangzhou 510006, China.
authors.forename: Xiao ou
authors.initials: Xo
authors.lastname: Sun
authors.affiliation: Pre-Incubator for Innovative Drug & Medicine, South China University of Technology, Guangzhou 510006, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Tian
authors.affiliation: Pre-Incubator for Innovative Drug & Medicine, South China University of Technology, Guangzhou 510006, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Pre-Incubator for Innovative Drug & Medicine, South China University of Technology, Guangzhou 510006, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.affiliation: Pre-Incubator for Innovative Drug & Medicine, South China University of Technology, Guangzhou 510006, China; Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, School of Bioscience & Bioengineering, South China University of Technology, Guangzhou 510006, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Tan
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D000077553:Edaravone; D004487:Edema / Q000473:pathology; D007150:Immunohistochemistry; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009474:Neurons / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D018696:Neuroprotective Agents; D000077553:Edaravone; D000983:Antipyrine